After receiving her MBA from the University of Pennsylvania’s The Wharton School and her Ph. D. from the University of California, JeanMarie Guenot began her career in science at Hoffmann-La Roche, where she was a principal scientist in Preclinical R&D. She worked at discovering and developing many drugs that addressed metabolic diseases, autoimmune diseases, oncology, and inflammation She received her training in medicinal and physical chemistry, focusing on semi-empirical methods and quantum mechanical methods for protein structure prediction, drug design, X-ray and NMR refinement, and molecular dynamics.
She began her business career by managing venture capital investments at Atlas Venture, where she also helped build life science companies. She has been a business advisor at Hoffman-La Roche in places like Shanghai and Basel. She was also the Vice President of Corporate and Business Development, leading licensing, mergers and acquisitions at PDL BioPharma’s R&D department. Guenot also led a co-development and co-commercialization collaboration at PDL that involved cancer and autoimmune disease drugs. This collaboration was a $800 million transaction that included a $100 million equity investment between PDL and Hoffman-La Roche. She was also involved in the licensing of ophthalmic indication for an oncology drug.
JeanMarie Guenot founded SKS Ocular. This start-up ophthalmic company focused on dry AMD, therapeutics and drug delivery technologies for macular degeneration, ocular inflammation, and glaucoma. SKS Ocular uses innovative research and development technologies to find and advance therapies through preclinical stages. Its mission is to transform current treatment methods for ocular diseases to provide new and more effective therapies that will sustain and improve patients’ vision.
CrunchBase describes Jeanmarie as having 20 years of experience in biotechnology and pharmaceutical industries, JeanMarie Guenot has worked in almost every stage of these fields. She has worked in both and public and private sectors, in corporate and commercial development, business development, project and alliance management, pharmaceutical R&D, and venture capital. Guenot has specialized focus on building and rebuilding companies.
She is currently the President and CEO of Amphivena Therapeutics, Inc. Amphivena was founded in 2013 and is a San Francisco-based preclinical stage treatment company. This innovative company works at developing bi-functional antibody therapies that address blood cancer indications that have high unmet medical needs. Amphivena has created relationships with other world class organizations that combine their strengths and industry resources into one focused network, with a passion for developing the best treatments and therapies for patients. Find Jeanmarie Guenot on social media, including Facebook.